Part: 12         Session: 145678910111213141516171819202122         Page 732733734735736737738739740741742743744745746747748749750751752753754755756757758759760761762763764765766767768769770771772773774775776777778779780781782783784785786787788789790791792 of 999

Either you'll get a very good result, or you'll find that something else in the material is helping. We don't know. So it's a great --

It's very promising.

It's very promising and also very nerve wracking, to find out whether interferon alone is doing what we see in .1 of 1 percent pure product.

Well, simultaneously, are they continuing to work with it in Finland and elsewhere in Europe?

Oh, yes.

And what results are they getting there?

Well, in Finland they don't do any clinical research. They sell their material all over the world. Any minute the Finnish government may say, “Oh well, we're going to keep all this in Finland,” but at present they're still supplying researchers, and the Swedes have got very good reults in osteogenic sarcoma, and in myeloma, and in some, a few lymphomas. They've had very striking responses, and they estimate that their results in osteogenic sarcoma (or bone cancer) in children or young people will result in a 50 percent disease free survival at five years. Now, if this material, plus the material that we're using like methotrexate and other more toxic drugs, were put together with interferon, you could have cures.

You could certainly have cures. And so this is what drives one to want to have enough material, pure material and also, to try to raise a lot of money to have even just the kind of material we have, as it is already prolonging life in some